The NCT00021255 study, which involved 3222 patients, showed that the addition of adjuvant trastuzumab for one year resulted in significant improvements in disease-free and overall survival rates among women diagnosed with HER2-positive breast cancer [113]. The gene discussed is ERBB2; the disease is breast cancer.